FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176798788> ?p ?o ?g. }

• W3176798788 endingPage "3095" @default.
• W3176798788 startingPage "3095" @default.
• W3176798788 abstract "Background: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC). Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the resulting radiopharmaceutical retention during RLT, but data confirming clinically significant renal toxicity are still lacking. In this study, patients with significantly impaired baseline kidney function before initiation of therapy were investigated for treatment-associated nephrotoxicity and the potential relationship with administered activities of [177Lu]Lu-PSMA-617. Methods: Twenty-two mCRPC patients with impaired renal function (glomerular filtration rate (GFR) ≤ 60 mL/min) who received more than two cycles of [177Lu]Lu-PSMA-617 RLT (median 5 cycles and median 6-week time interval between consecutive cycles) were analyzed in this study. Patients were treated within a prospective patient registry (REALITY Study, NCT04833517). Cumulative administered activities ranged from 17.1 to 85.6 GBq with a median activity of 6.5 GBq per cycle. Renal function was closely monitored during and after PSMA-RLT. Results: Mean pre-treatment GFR was 45.0 ± 10.7 mL/min. After two (22/22 patients), four (20/22 patients), and six cycles (10/22 patients) of RLT, a significant increase of GFR was noted (each p < 0.05). End-of-treatment GFR (54.1 ± 16.7 mL/min) was significantly higher than baseline GFR (p = 0.016). Only one patient experienced deterioration of renal function (change of CTCAE grade 2 to 3). The remaining patients showed no significant reduction of GFR, including follow-up assessments (6, 9, and 12 months), and even showed improved (10/22 patients) or unchanged (11/22 patients) CTCAE-based renal impairment grades during and after the end of PSMA-RLT. No significant correlation between the change in GFR and per-cycle (p = 0.605) or cumulative (p = 0.132) administered activities were found. Conclusions: As pre-treatment chronic kidney failure did not lead to detectable RLT-induced deterioration of renal function in our study, the nephrotoxic potential of [177Lu]Lu-PSMA-617 RLT may be overestimated and not of clinical priority in the setting of palliative treatment in mCRPC. We suggest not to categorically exclude patients from enrolment to PSMA-RLT due to renal impairment." @default.
• W3176798788 created "2021-07-05" @default.
• W3176798788 creator A5015741098 @default.
• W3176798788 creator A5039482910 @default.
• W3176798788 creator A5051737896 @default.
• W3176798788 creator A5065508393 @default.
• W3176798788 creator A5068245115 @default.
• W3176798788 creator A5079714111 @default.
• W3176798788 creator A5082113605 @default.
• W3176798788 creator A5083810061 @default.
• W3176798788 date "2021-06-21" @default.
• W3176798788 modified "2023-09-27" @default.
• W3176798788 title "Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function" @default.
• W3176798788 cites W1140456871 @default.
• W3176798788 cites W1969170786 @default.
• W3176798788 cites W1982355609 @default.
• W3176798788 cites W2055864845 @default.
• W3176798788 cites W2110534364 @default.
• W3176798788 cites W2120292596 @default.
• W3176798788 cites W2148643283 @default.
• W3176798788 cites W2155421560 @default.
• W3176798788 cites W2165542862 @default.
• W3176798788 cites W2274307715 @default.
• W3176798788 cites W2278817559 @default.
• W3176798788 cites W2304896218 @default.
• W3176798788 cites W2346293763 @default.
• W3176798788 cites W2467227824 @default.
• W3176798788 cites W2518199070 @default.
• W3176798788 cites W2520024435 @default.
• W3176798788 cites W2523192478 @default.
• W3176798788 cites W2523307075 @default.
• W3176798788 cites W2523333323 @default.
• W3176798788 cites W2532226140 @default.
• W3176798788 cites W2544324436 @default.
• W3176798788 cites W2599305587 @default.
• W3176798788 cites W2623767334 @default.
• W3176798788 cites W2625296464 @default.
• W3176798788 cites W2725251074 @default.
• W3176798788 cites W2731354724 @default.
• W3176798788 cites W2771847508 @default.
• W3176798788 cites W2799931007 @default.
• W3176798788 cites W2895593497 @default.
• W3176798788 cites W2902367783 @default.
• W3176798788 cites W2921719389 @default.
• W3176798788 cites W2967473900 @default.
• W3176798788 cites W2969742213 @default.
• W3176798788 cites W2988034537 @default.
• W3176798788 cites W3005616683 @default.
• W3176798788 doi "https://doi.org/10.3390/cancers13123095" @default.
• W3176798788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8235711" @default.
• W3176798788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34205686" @default.
• W3176798788 hasPublicationYear "2021" @default.
• W3176798788 type Work @default.
• W3176798788 sameAs 3176798788 @default.
• W3176798788 citedByCount "23" @default.
• W3176798788 countsByYear W31767987882021 @default.
• W3176798788 countsByYear W31767987882022 @default.
• W3176798788 countsByYear W31767987882023 @default.
• W3176798788 crossrefType "journal-article" @default.
• W3176798788 hasAuthorship W3176798788A5015741098 @default.
• W3176798788 hasAuthorship W3176798788A5039482910 @default.
• W3176798788 hasAuthorship W3176798788A5051737896 @default.
• W3176798788 hasAuthorship W3176798788A5065508393 @default.
• W3176798788 hasAuthorship W3176798788A5068245115 @default.
• W3176798788 hasAuthorship W3176798788A5079714111 @default.
• W3176798788 hasAuthorship W3176798788A5082113605 @default.
• W3176798788 hasAuthorship W3176798788A5083810061 @default.
• W3176798788 hasBestOaLocation W31767987881 @default.
• W3176798788 hasConcept C126189478 @default.
• W3176798788 hasConcept C126322002 @default.
• W3176798788 hasConcept C126894567 @default.
• W3176798788 hasConcept C159641895 @default.
• W3176798788 hasConcept C188816634 @default.
• W3176798788 hasConcept C2780091579 @default.
• W3176798788 hasConcept C71924100 @default.
• W3176798788 hasConceptScore W3176798788C126189478 @default.
• W3176798788 hasConceptScore W3176798788C126322002 @default.
• W3176798788 hasConceptScore W3176798788C126894567 @default.
• W3176798788 hasConceptScore W3176798788C159641895 @default.
• W3176798788 hasConceptScore W3176798788C188816634 @default.
• W3176798788 hasConceptScore W3176798788C2780091579 @default.
• W3176798788 hasConceptScore W3176798788C71924100 @default.
• W3176798788 hasIssue "12" @default.
• W3176798788 hasLocation W31767987881 @default.
• W3176798788 hasLocation W31767987882 @default.
• W3176798788 hasLocation W31767987883 @default.
• W3176798788 hasOpenAccess W3176798788 @default.
• W3176798788 hasPrimaryLocation W31767987881 @default.
• W3176798788 hasRelatedWork W1987388617 @default.
• W3176798788 hasRelatedWork W1998705322 @default.
• W3176798788 hasRelatedWork W2025464329 @default.
• W3176798788 hasRelatedWork W2076545639 @default.
• W3176798788 hasRelatedWork W2093874596 @default.
• W3176798788 hasRelatedWork W2158384701 @default.
• W3176798788 hasRelatedWork W2184922026 @default.
• W3176798788 hasRelatedWork W2396590096 @default.
• W3176798788 hasRelatedWork W2408829444 @default.
• W3176798788 hasRelatedWork W2566477261 @default.

• next